Citi analyst Joanne Wuensch raised the firm’s price target on DexCom (DXCM) to $84 from $77 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom Executive Chairman Kevin Sayer Returns From Leave
- Dexcom Adds Google Executive Rick Osterloh to Board
- DexCom management to meet virtually with BTIG
- Dexcom’s $750 Million 2025 Buyback Plan Faces Uncertain Execution and Limited Assurance of Shareholder Value
- DexCom Earnings Call Highlights Margin Rebound, Growth